Downregulation of lncRNA PVT1 inhibits proliferation and migration of mesothelioma cells by targeting FOXM1. 2022

Yutaro Fujii, and Vishwa Jeet Amatya, and Kei Kushitani, and Rui Suzuki, and Yuichiro Kai, and Takahiro Kambara, and Yukio Takeshima
Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734‑8551, Japan.

Malignant mesothelioma is a highly aggressive tumor, and an effective strategy for its treatment is not yet available. Long non‑coding RNAs (lncRNAs) have been reported to be associated with various biological processes, including the regulation of gene expression of cancer‑related pathways. Among various lncRNAs, plasmacytoma variant translocation 1 (PVT1) acts as a tumor promoter in several human cancers, but its mechanism of action has not yet been elucidated. Increased PVT1 expression was identified in ACC‑MESO‑1, ACC‑MESO‑4, CRL‑5915, and CRL‑5946 mesothelioma cell lines. PVT1 expression was investigated in mesothelioma cell lines by reverse transcription‑quantitative polymerase chain reaction and its functional analysis by cell proliferation, cell cycle, cell migration, and cell invasion assays, as well as western blot analysis of downstream target genes. Knockdown of PVT1 expression in these cell lines by small interfering RNA transfection resulted in decreased cell proliferation and migration and increased the proportion of cells in the G2/M phase. The results of reverse transcription‑quantitative polymerase chain reaction analysis revealed that PVT1 knockdown in mesothelioma cell lines caused the downregulation of Forkhead box M1 (FOXM1) expression, while the results of western blot analysis revealed that this knockdown reduced FOXM1 expression at the protein level. In addition, combined knockdown of PVT1 and FOXM1 decreased the proliferation of mesothelioma cell lines. In conclusion, PVT1 and FOXM1 were involved in the proliferation of cancer cells. Therefore, PVT1‑FOXM1 pathways may be considered as candidate targets for the treatment of malignant mesothelioma.

UI MeSH Term Description Entries
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072278 Forkhead Box Protein M1 A forkhead box transcription factor that is expressed primarily in adult organs which contain proliferating cells such as the thymus, testis, ovary, and small intestine. It controls the expression of CELL CYCLE genes essential for DNA REPLICATION and MITOSIS, and also functions in DNA REPAIR. FOXM1 Protein
D000086002 Mesothelioma, Malignant A type of mesothelioma with a tendency to metastasize. Most tumors originate from either the PLEURA or PERITONEUM, tumors may also originate in the PERICARDIUM or testicular tissue. It is associated with ASBESTOS exposure. Somatic mutations identified in WT1, BCL10, CDKN2A, NF2, and BAP1 genes are associated with the malignancy. OMIM: 156240. Malignant Mesothelioma,Malignant Pleural Mesothelioma,Mesothelioma, Malignant Pleural,Malignant Mesotheliomas,Malignant Pleural Mesotheliomas,Mesotheliomas, Malignant,Mesotheliomas, Malignant Pleural,Pleural Mesothelioma, Malignant,Pleural Mesotheliomas, Malignant
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D062085 RNA, Long Noncoding A class of untranslated RNA molecules that are typically greater than 200 nucleotides in length and do not code for proteins. Members of this class have been found to play roles in transcriptional regulation, post-transcriptional processing, CHROMATIN REMODELING, and in the epigenetic control of chromatin. LincRNA,RNA, Long Untranslated,LINC RNA,LincRNAs,Long Intergenic Non-Protein Coding RNA,Long Non-Coding RNA,Long Non-Protein-Coding RNA,Long Noncoding RNA,Long ncRNA,Long ncRNAs,RNA, Long Non-Translated,lncRNA,Long Intergenic Non Protein Coding RNA,Long Non Coding RNA,Long Non Protein Coding RNA,Long Non-Translated RNA,Long Untranslated RNA,Non-Coding RNA, Long,Non-Protein-Coding RNA, Long,Non-Translated RNA, Long,Noncoding RNA, Long,RNA, Long Non Translated,RNA, Long Non-Coding,RNA, Long Non-Protein-Coding,Untranslated RNA, Long,ncRNA, Long,ncRNAs, Long

Related Publications

Yutaro Fujii, and Vishwa Jeet Amatya, and Kei Kushitani, and Rui Suzuki, and Yuichiro Kai, and Takahiro Kambara, and Yukio Takeshima
October 2018, Oncology letters,
Yutaro Fujii, and Vishwa Jeet Amatya, and Kei Kushitani, and Rui Suzuki, and Yuichiro Kai, and Takahiro Kambara, and Yukio Takeshima
January 2022, Canadian journal of gastroenterology & hepatology,
Yutaro Fujii, and Vishwa Jeet Amatya, and Kei Kushitani, and Rui Suzuki, and Yuichiro Kai, and Takahiro Kambara, and Yukio Takeshima
May 2020, Bioscience reports,
Yutaro Fujii, and Vishwa Jeet Amatya, and Kei Kushitani, and Rui Suzuki, and Yuichiro Kai, and Takahiro Kambara, and Yukio Takeshima
June 2020, Bioscience reports,
Yutaro Fujii, and Vishwa Jeet Amatya, and Kei Kushitani, and Rui Suzuki, and Yuichiro Kai, and Takahiro Kambara, and Yukio Takeshima
January 2018, American journal of translational research,
Yutaro Fujii, and Vishwa Jeet Amatya, and Kei Kushitani, and Rui Suzuki, and Yuichiro Kai, and Takahiro Kambara, and Yukio Takeshima
August 2018, Journal of cellular and molecular medicine,
Yutaro Fujii, and Vishwa Jeet Amatya, and Kei Kushitani, and Rui Suzuki, and Yuichiro Kai, and Takahiro Kambara, and Yukio Takeshima
March 2017, Oncology reports,
Yutaro Fujii, and Vishwa Jeet Amatya, and Kei Kushitani, and Rui Suzuki, and Yuichiro Kai, and Takahiro Kambara, and Yukio Takeshima
January 2021, OncoTargets and therapy,
Yutaro Fujii, and Vishwa Jeet Amatya, and Kei Kushitani, and Rui Suzuki, and Yuichiro Kai, and Takahiro Kambara, and Yukio Takeshima
January 2021, Current pharmaceutical biotechnology,
Yutaro Fujii, and Vishwa Jeet Amatya, and Kei Kushitani, and Rui Suzuki, and Yuichiro Kai, and Takahiro Kambara, and Yukio Takeshima
February 2020, Anti-cancer drugs,
Copied contents to your clipboard!